Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes
NCT00324389 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2
Last updated 2010-08-27
Summary
This proposal seeks to use DNA analyses to understand how racial and genetic factors influence interferon (treatment) response in HCV infection in African Americans. A better understanding should allow rational design of new therapies or better use of existing therapies. Patients will provide medical history and undergo a physical exam, blood draws, electrocardiogram, possible chest x-ray, and abdominal ultrasound. Patients will be admitted to the hospital for 5 days and undergo 2 liver biopsies, sedation, and multiple blood draws. Twenty adult male volunteers (10 Caucasians,10 African Americans) ages 18 - 65 years will participate.
Conditions
- Hepatitis C
Interventions
- DRUG
-
Interferon alpha
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-05-31
- Completion
- 2006-06-30
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)
NCT00828269 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)
NCT00328549 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
NCT00001035 ·Status: COMPLETED ·Phase: PHASE1
-
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
NCT00381953 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients
NCT00703560 ·Status: COMPLETED
-
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
NCT00493805 ·Status: TERMINATED ·Phase: PHASE4
-
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
NCT01285050 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
NCT00100581 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
NCT00217139 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
NCT00803309 ·Status: TERMINATED ·Phase: PHASE4
-
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
NCT00292084 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
NCT02532907 ·Status: COMPLETED
-
Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients
NCT01758939 ·Status: UNKNOWN
-
Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
NCT02590068 ·Status: TERMINATED ·Phase: NA
-
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
NCT00008463 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood
NCT02718573 ·Status: COMPLETED
-
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)
NCT00705224 ·Status: COMPLETED
-
Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile
NCT00272389 ·Status: UNKNOWN
-
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
NCT02429583 ·Status: TERMINATED ·Phase: PHASE4
-
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
NCT00834860 ·Status: UNKNOWN ·Phase: PHASE4
-
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
NCT01384383 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
NCT02340962 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)
NCT00635804 ·Status: COMPLETED ·Phase: PHASE1
-
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
NCT01467492 ·Status: TERMINATED ·Phase: PHASE4
-
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
NCT00718172 ·Status: COMPLETED ·Phase: PHASE1